ClinicalTrials.gg
TerminatedNCT03897062Updated Feb 15, 2023

Suvorexant in the Management Comorbid Sleep Disorder and Alcohol Dependence

A Phase 2 interventional study of Suvorexant 20 mg and placebo in Insomnia and Alcohol Use Disorder, sponsored by The Florey Institute of Neuroscience and Mental Health. Terminated at 1 site in Australia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by The Florey Institute of Neuroscience and Mental Health · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Recruitment problems during covid lockdowns resulted in Merck ceasing supply of suvorexant/placebo

From the registry’s dates

  • Primary completion was Jul 2022, 4 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders — 5 open to participants now, 5 under way, 1 of them phase 3. suvorexant · Sleep Initiation and Maintenance Disorders.

Enrollment
29th of 38
22 · median 44
Started
2019
with 5 others
Phase 2
6 of 38
2 open now
Registered
24th of 38
by date

Among the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, this one is the 29th largest by enrollment, is one of 6 that started in 2019, is one of 6 in phase 2, and was the 24th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

5 of the 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About suvorexant

suvorexant: first FDA approval 2014 (BELSOMRA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing suvorexant in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

Suvorexant (trade name Belsomra) is an orexin receptor antagonist that has TGA approval for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. It may also have a role in addictions as the orexins play a critical role in drug addiction and reward-related behaviours. Orexins appear to be involved in both alcohol withdrawal and in alcohol seeking triggered by external cues (eg contexts or stressors) through both OX1 and OX2 receptor signalling. Chief investigator, Professor Lawrence was the first to demonstrate a role for endogenous orexin signaling in alcohol-seeking. Alcohol is known to effect the sleep of healthy and alcohol dependent individuals with effects on daytime sleepiness, physiological functions during sleep, and the development of sleep disorders. There are various estimates of the co-occurrence of insomnia and alcohol use disorder ranging from 36-72%. In alcohol dependent individuals sleep is disturbed both while drinking and for months of abstinence and abstinent sleep disturbance is predictive of relapse.

This proposal aims to evaluate the use of suvorexant as a safe and effective pharmacotherapy to treat sleep disorders in alcohol dependent patients undergoing acute alcohol withdrawal and thereafter for six months. The study will also examine the effectiveness of suvorexant in reducing craving for alcohol and promoting duration of abstinence. This will be the first double blind controlled trial of suvorexant in the management of the alcohol withdrawal syndrome and maintenance of abstinence post withdrawal.

Read the detailed description

Study Procedures Baseline On Day 1, prior to commencement of treatment baseline data will be collected on demographics, ISI questionnaire plus 2 short questions 1) how many hours sleep has the participant had for the past week; 2) how would the participant rate their sleep quality in the past week. The investigators will also determine previous drug use history, physical examination, urine drug screen and measures of alcohol dependence severity, psychological and social functioning (ATOPv7).

Treatment Period Treatment will begin immediately after collection of Baseline data. Suvorexant will not be given if breath alcohol concentration is above zero. Both groups will be treated using the St Vincent's Hospital standard protocol for management of alcohol withdrawal, in which benzodiazepines are provided as required according to the symptoms listed in the Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). That is, if the CIWA-Ar score is > 10 then benzodiazepines (BZD) are administered. Note, BZD will not be given for management of insomnia. Physicians involved in patient care, nurses and participants will be blinded to treatment assignment. Participants will be monitored for signs of adverse events (i.e. distress, significant alcohol withdrawal, and adverse response to suvorexant) approximately 4 hourly for the first 24 - 48 hrs of residential stay and then according to clinical assessment. All clinical observations will be made by a suitably qualified and experienced medical professional. Where any adverse events are observed, monitoring will be increased to meet clinical needs and treatment discontinued if required. Alcohol withdrawal severity will be assessed using the Clinical Institute Withdrawal Assessment - Alcohol revised (CIWA-Ar).

Note, during in-patient assessment there will be no consumption of alcohol (7-10 days). Upon release to outpatients the investigators will advise participants not to consume alcohol and will provide follow-up support to help maintain abstinence. If patients resume heavy drinking and are deemed to have relapsed i.e. daily alcohol consumption greater than 5 standard drinks each day, the investigators will tell them to cease the medication and they will be withdrawn from the study. Data collected to this point will be included in the study.

Follow-up Treatment Subsequent follow-up would occur weekly for 4 weeks post inpatient treatment and then every 4 weeks to week 25. Patients will continue the same dose of Suvorexant/placebo for the duration of the follow-up period. At the end of the 25 week trial patients will continue to receive treatment as usual. If they wish to continue to receive suvorexant they can get a prescription from their GP (suvorexant has been added to the pharmaceutical benefits scheme).

Data Collection Baseline

  • Name, date of birth, gender, contact details.
  • ISI Insomnia Severity Index questionnaire (modified)
  • Substance use history, medical history including current medications.
  • Psychosocial status (data routinely collected through national minimum data set)
  • Past history withdrawal symptoms ("delirium tremens", "seizures" etc)
  • DSM 5 criteria for alcohol use disorder (AUD)
  • Structured clinical Interview for DSm-5 (SCID-5)
  • Pittsburgh Sleep Quality Index (PSQI)
  • Epworth Sleepiness Scale
  • K10 (Kessler Psychological Distress Scale), 10 questions about psychological distress symptoms: baseline and daily while in alcohol withdrawal then at monthly follow up
  • ATOP Australian Treatment Outcome Profile
  • Breath alcohol reading
  • Liver function test
  • Urine drug screen

In-patient withdrawal:

  • Actigraphy measures of sleep patterns (Externally worn non-invasive accelerometer and light exposure recorder worn continually, from the first day of admission to discharge).
  • Portable Polysomnography (Multichannel recoding of the electrophysiological markers of sleep). Polysomnography (PSG) records brain activity, eye movements and muscle tone to identify stages of sleep. In addition leg movements, heart rhythm, pulse rate, oxygen saturation, nasal breath flow, snore and chest movements are used to identify respiratory activity and lower leg muscle activity is also monitored for disturbing movements. (Day 1 and Day 7)
  • Epworth Sleepiness Scale (excessive daytime sleepiness)
  • Sleep diary during their stay (seven-ten days)
  • ISI Insomnia questionnaire (Day 7 only)
  • Clinical Information (as per open ended questioning for all AE's)
  • CIWA-Ar (revised Clinical Institute Withdrawal Assessment for Alcohol scale), 10-item assessment of severity of alcohol withdrawal: baseline and every 2 - 4 hours, performed by trained staff
  • Craving for alcohol using Obsessive Compulsive Drinking Scale
  • Kessler 10 measure of psychological distress (Day 7 last 3 days)

At weekly follow-up, for weeks 2 to 5 and at monthly follow-up from week 9 to 25

  • Pittsburgh Sleep Quality Index (sleep quality) (Wk5,9,13,17,21,25)
  • Epworth Sleepiness Scale on admission (excessive daytime sleepiness)
  • Sleep diary \& ISI insomnia questionnaire
  • Additional 2 short questions will be collected:

    • how many hours sleep has the participant had for the past week;
    • how would the participant rate their sleep quality in the past week;
  • Clinical Information (as per open ended questioning for SAE safety data suvorexant form)
  • Alcohol and other substance use (self report)
  • ATOP Australian Treatment Outcome Profile (Wk5,9,13,17,21,25)
  • K10 (Kessler Psychological Distress Scale)
  • Breath alcohol reading
  • Urine drug screen
  • Liver/renal function tests (Wk 2,5,9,13,17,21,25)
  • Craving for alcohol using Obsessive Compulsive Drinking Scale

Any differences between objective and subjective sleep measures will be documented and reflected back to patients on an individual basis. During the consent process all patients will be informed that this is a trial and that there will be no additional (other than the trial) medication provided for insomnia.

03

Conditions studied

  • Insomnia
  • Alcohol Use Disorder

Keywords

  • suvorexant
  • insomnia
  • alcohol use disorder
  • craving
  • withdrawal
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years of age and not more than 75 years of age
  • diagnosis of insomnia
  • Alcohol dependent (SCID-5)
  • Willing to comply with treatment and follow-up requirements of study
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Consumes less than 6 standard drinks per day.
  • Not alcohol dependent (SCID-5)
  • Unstable major psychiatric disorder e.g. active psychosis, significant PTSD.
  • Currently taking medication having major interaction with suvorexant
  • Pregnant (urine βHCG positive) or not using adequate .
  • Breast feeding.
  • Severe hepatic impairment (Liver enzyme levels >five times normal level)
  • Severe renal impairment (urine \< 30ml/h)
  • Severe medical disorder e.g. epilepsy, cardiovascular disorder
  • Participating in another pharmacotherapy trial e.g. lorcaserin
  • Highly dependent on medical care.
  • Driver of any vehicle (car or commercial vehicle)
  • Inability to take oral medication.
  • No consent to participate in the study
  • Known sensitivity to suvorexant.
  • Less than 18 years of age
  • Over 75 years of age.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Treatment group

    Patients (n=64): 20mg tablets of suvorexant nocte daily for six months

    Drug: Suvorexant 20 mg

  • Placebo comparator
    Placebo group

    Placebo control group: Patients (n=64): 1 placebo tablet nocte daily for six months in addition to treatment as usual

    Other: placebo

Interventions

  • DrugSuvorexantStudies of SuvorexantSuvorexant pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Placebo controlled double blind suvorexant vs placebo

  • Otherplacebo

    Placebo controlled double blind suvorexant vs placebo

06

What researchers measure

Primary outcomes

  1. Sleep measure

    Change in polysomnography sleep efficiency measure from baseline and at end of inpatient stay. Portable Polysomnography is multichannel recording of the electrophysiological markers of sleep. Polysomnography (PSG) records brain activity, eye movements and muscle tone to identify stages of sleep. Sleep efficiency measure is number of minutes of sleep divided by the number of minutes in bed {%}).

    Time frame: 7-10 days

Secondary outcomes

  1. Sleep measure

    Changed ISI scores from baseline at end of inpatient stay plus at 5 weeks, 9, 13, 17, 21, 25 weeks. The ISI is 7 questions (0-4) with a maximum score of 28 for severe insomnia. The investigators anticipate a change in total score.

    Time frame: 25 weeks

  2. Sleep quality: Pittsburgh Sleep Quality Index (PSQI)

    Changed Pittsburgh Sleep Quality Index (PSQI) scores from baseline at end of inpatient stay plus at 5 weeks, 9, 13, 17, 21, 25 weeks. The PSQI is a battery of 9 questions (scores 0-3). A total score of 5 or more indicates poor sleep. The investigators anticipate a change in total score.

    Time frame: 25 weeks

  3. Sleepiness measure

    Changed Epworth Sleepiness Scale scores from baseline at end of inpatient stay plus at 5 weeks, 9, 13, 17, 21, 25 weeks. There are 8 questions with scores of 0-3, maximum score of 24 indicates excessive sleepiness. A change in total score is anticipated.

    Time frame: 25 weeks

  4. Abstinence measure

    Abstinence rates from baseline at 5 weeks, 9, 13, 17, 21, 25 weeks (%)

    Time frame: 25 weeks

  5. Relapse measure

    Relapse to heavy drinking (\>5 drinks/day) from baseline to 5 weeks, 9, 13, 17, 21, 25 weeks

    Time frame: 25 weeks

  6. Craving measure

    Change in alcohol craving measures using the Obsessive Compulsive Drinking Scale from baseline at 5 weeks, 9, 13, 17, 21, 25 weeks. This scale is made up of 14 questions (0-4 range). The higher the total score, the greater the craving. The investigators anticipate a change in total score.

    Time frame: 25 weeks

  7. Liver function measure

    Liver function change \[Aspartate aminotransferase (AST) and Gamma-glutamyltransferase (GGT) levels\] from baseline at 5 weeks, 9, 13, 17, 21, 25 weeks (%)

    Time frame: 25 weeks

  8. Urine drug screen

    Urine drug screens negative for drugs other than alcohol from baseline at 5 weeks, 9, 13, 17, 21, 25 weeks (%)

    Time frame: 25 weeks

07

Study locations

1 site
  • St Vincent's Hospital
    Melbourne, Victoria 3065, Australia
08

References and documents

Publications

  • Walker LC, Lawrence AJ. The Role of Orexins/Hypocretins in Alcohol Use and Abuse. Curr Top Behav Neurosci. 2017;33:221-246. doi: 10.1007/7854_2016_55. PubMed 27909991 ↗
  • Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B. The orexin system regulates alcohol-seeking in rats. Br J Pharmacol. 2006 Jul;148(6):752-9. doi: 10.1038/sj.bjp.0706789. Epub 2006 Jun 5. PubMed 16751790 ↗
  • von der Goltz C, Koopmann A, Dinter C, Richter A, Grosshans M, Fink T, Wiedemann K, Kiefer F. Involvement of orexin in the regulation of stress, depression and reward in alcohol dependence. Horm Behav. 2011 Nov;60(5):644-50. doi: 10.1016/j.yhbeh.2011.08.017. Epub 2011 Sep 16. PubMed 21945150 ↗
  • Brower KJ. Insomnia, alcoholism and relapse. Sleep Med Rev. 2003 Dec;7(6):523-39. doi: 10.1016/s1087-0792(03)90005-0. PubMed 15018094 ↗
  • Roehrs T, Roth T. Sleep, sleepiness, and alcohol use. Alcohol Res Health. 2001;25(2):101-9. PubMed 11584549 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Jul 2022, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2019
First posted
Apr 1, 2019
StartActual
Aug 26, 2019
Primary completionActual
Jul 31, 2022
CompletionActual
Jul 31, 2022
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03897062
Lead sponsor
The Florey Institute of Neuroscience and Mental Health
Collaborators
St Vincent's Hospital Melbourne, Melbourne Health
Responsible party
Sponsor
First posted
Apr 1, 2019
Start date
Aug 26, 2019
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Last update
Feb 15, 2023

Study contacts

Andrew Lawrence
principal investigator · Florey Institute of Neuroscience & Mental Health
Yvonne Bonomo
principal investigator · St Vincent's Hospital Melbourne

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Suvorexant

Start the discussion